GANX Logo

Gain Therapeutics, Inc. (GANX) 

NASDAQ
Market Cap
$22.93M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
262 of 809
Rank in Industry
154 of 445

Largest Insider Buys in Sector

GANX Stock Price History Chart

GANX Stock Performance

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Insider Activity of Gain Therapeutics, Inc.

Over the last 12 months, insiders at Gain Therapeutics, Inc. have bought $115,770 and sold $5,057 worth of Gain Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Gain Therapeutics, Inc. have bought $97,592 and sold $5,057 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Riley Jeffrey Scott (director) — $115,770.

The last purchase of 30,000 shares for transaction amount of $115,770 was made by Riley Jeffrey Scott (director) on 2024‑03‑28.

List of Insider Buy and Sell Transactions, Gain Therapeutics, Inc.

2024-03-28PurchaseRiley Jeffrey Scottdirector
30,000
0.1501%
$3.86$115,770-30.37%
2023-12-21SaleAlder MatthiasChief Executive Officer
206
0.0014%
$2.46$507+36.49%
2023-12-07SaleAlder MatthiasChief Executive Officer
1,820
0.0122%
$2.50$4,550+32.16%
2022-05-25PurchaseRICHMAN ERIC ICHIEF EXECUTIVE OFFICER
2,482
0.0203%
$2.58$6,404+43.21%
2022-05-19PurchaseRICHMAN ERIC ICHIEF EXECUTIVE OFFICER
9,256
0.0816%
$2.83$26,194+39.63%
2022-05-19PurchaseCalabrese SalvatoreCHIEF FINANCIAL OFFICER
3,000
0.0252%
$2.70$8,100+39.63%
2021-08-16PurchaseRICHMAN ERIC IChief Executive Officer
4,922
0.042%
$7.87$38,716-45.68%

Insider Historical Profitability

19.2%
Riley Jeffrey Scottdirector
30000
0.185%
$1.2710
Alder MatthiasChief Executive Officer
5286
0.0258%
$1.2702
RICHMAN ERIC ICHIEF EXECUTIVE OFFICER
217729
1.0644%
$1.2730+12.38%
Calabrese SalvatoreCHIEF FINANCIAL OFFICER
3000
0.0147%
$1.2710+39.63%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Raymond James Associates$980,272.001.44260,019+993.07%+$890,591.21<0.01
Royal Bank of Canada$937,000.001.38248,500+24.1%+$181,940.14<0.0001
Geode Capital Management$667,734.000.98177,091+16.91%+$96,583.15<0.0001
The Vanguard Group$450,003.000.66119,364+35.05%+$116,791.02<0.0001
Cm Management Llc$339,300.000.590,0000%+$00.02
BlackRock$284,251.000.4275,398+173.07%+$180,157.33<0.0001
Renaissance Technologies$176,000.000.2646,700+9.11%+$14,698.07<0.0001
Northern Trust$175,253.000.2646,486+6.83%+$11,208.26<0.0001
Millennium Management LLC$167,448.000.2544,416+247.98%+$119,327.81<0.0001
Susquehanna International Group$162,344.000.2443,062+24.82%+$32,278.79<0.0001
Prelude Capital$135,041.000.235,820-38.35%-$83,995.350.01
State Street$116,255.000.1730,837New+$116,255.00<0.0001
Bridgeway Capital Management$113,100.000.1730,000-34.92%-$60,697.00<0.01
Simplex Trading Llc$67,000.000.117,983New+$67,000.00<0.01
UBS$32,697.000.058,673-38.15%-$20,169.37<0.0001
Tower Research Capital$17,463.000.034,632-5.32%-$980.22<0.0001
Citadel Advisors LLC$15,921.000.024,223-93.54%-$230,618.87<0.0001
Wells Fargo$14,161.000.023,756+0.78%+$109.34<0.0001
Bank of America$12,724.000.023,375New+$12,724.00<0.0001
Morgan Stanley$10,556.000.022,8000%+$0<0.0001
Group One Trading$7,544.000.012,001-49.17%-$7,298.94<0.0001
Citigroup$2,579.00<0.01684New+$2,579.00<0.0001
Newedge Advisors Llc$848.00<0.01225New+$848.00<0.0001